Recent patent applications in RNA interference

Patent #	Subject	Assignee(s)	Inventor(s)	Priority application date	Publication date
US 20060240556	A method of making a nuclear transfer embryo comprising stably transfecting a construct to mediate RNA interference of a target gene or gene transcript expressed in the particular lineage into the cell.	Advanced Cell Technology (Alameda, CA, USA)	Cibelli J	3/8/2001	6/22/2006
WO 2006128739	New oligonucleotide compositions for RNA interference, comprising double-stranded oligonucleotides of identical or different sequences and/or length; useful for inhibiting gene expression for treating cancers or viral infections.	Polyplus-Transfection (Illkirch, France)	Behr J, Bolcato Bellemin A, Erbacher P	6/1/2005	6/1/2006
WO 2006128141	A new double-stranded nucleic acid molecule for treating stromal cell–derived, factor-1–mediated condition (e.g., cancer), comprising a sense strand and an antisense strand with a sequence complementary to the RNA of factor-1, with both having specific nucleotides.	Sirna Therapeutics (San Francisco, CA, USA)	Guerciolini R, Jadhav V, McSwiggen J, Vargeese C	5/27/2005	5/26/2006
WO 2006126600	A pharmaceutical composition for treating vascular occlusive disease, comprising a nucleic acid construct capable of inhibiting the expression of a midkine gene through RNA interference in the presence of the collagen molecule.	Cell Signals (Yokohama, Japan), National University Corp. of Nagoya University (Nagoya, Japan)	Banno H, Kadomatsu K, Komori K, Muramatsu T, Sakuma S, Takei Y	5/25/2005	5/24/2006
WO 2006123800	An RNA interference induction element for producing a short interfering RNA for a target gene, with a nucleotide sequence that has the nucleic acid of a DNA sequence with specified base pairs, continuous nucleotides or specified homology.	Japan Science and Technology Agency (Kawaguchi, Japan), Kurume University (Kurume, Japan)	Ishii K, Takahashi K	5/18/2005	5/15/2006
WO 2006110813	A composition comprising a nucleic acid agent capable of inhibiting the expression via RNA interference of gene that enhances unwanted neovascularization; useful for treating cancer, ocular diseases, arthritis or inflammatory diseases.	Intradigm (Rockville, MD, USA)	Lui Y, Scaria PV, Schiffelers R, Tang QQ, Woodle MC, Xie FY, Xu J, Yang Lu P, Zhou Q	4/12/2005	4/12/2006
US 20060234973	A method for inhibiting E2F1 polypeptide expression for treating, ameliorating or preventing inflammatory disorders, etc., comprising contacting the cell or tissue with an RNA interference reagent.	Fitzgerald K, Guo Q, Jackson DG	Fitzgerald K, Guo Q, Jackson DG	4/14/2005	4/12/2006
WO 2006110688	An RNA interference-inducing molecule targeted to a transcript of a respiratory virus; useful for preventing or treating viral infections, including human respiratory syncytial virus, rhinovirus and influenza infections.	Nastech Pharmaceutical (Bothell, WA, USA)	Ge Q, Kumar M, McSwiggen JA	4/8/2005	4/7/2006
WO 2006105361	A new nucleic acid for treating diseases associated with unwanted proliferation of cells (e.g., cancer) comprising a double-stranded nucleic acid that reduces ribonucleotide reductase subunit expression by RNA interference.	Calando Pharmaceuticals (Duarte, CA, USA)	Davis ME, Heidel JD, Rossi JJ	3/31/2005	3/31/2006
US 20060241075	A new short interfering RNA useful for studying, diagnosing and treating diseases that respond to the Desmoglein gene expression and/or activity (e.g., alopecia or dermatological disease).	Sirna Therapeutics (San Francisco, CA, USA)	McSwiggen J	5/18/2001	10/26/2005
US 20060264396	A composition useful in the treatment or prevention of endometrial cancer, comprising a nucleic acid molecule inducing RNA interference against human syndecan-1 gene expression, and a carrier.	Ajou University Industry Cooperation Foundation (Suwon, Korea)	Choi DS, Min CK	5/18/2005	8/22/2005

Source: Thomson Scientific Search Service (formerly Derwent). The status of each application is slightly different from country to country. For further details, contact Thomson Scientific, 1725 Duke Street, Suite 250, Alexandria, Virginia 22314, USA. Tel: 1 (800) DERWENT (http://www.thomson.com/scientific).